close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Sanofi - Aventis Groupe

< Previous 1 2 3 4 5 Next >
News headline image
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Annual General Meeting of April 30, 2024
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Availability of the Q4 2023 Memorandum for modelling purposes
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sanofi Enters Next Chapter of Play to Win Strategy
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
From Sanofi - Aventis Groupe
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today